US2779780A
(en)
|
1955-03-01 |
1957-01-29 |
Du Pont |
1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
|
US4261989A
(en)
|
1979-02-19 |
1981-04-14 |
Kaken Chemical Co. Ltd. |
Geldanamycin derivatives and antitumor drug
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
US4880078A
(en)
|
1987-06-29 |
1989-11-14 |
Honda Giken Kogyo Kabushiki Kaisha |
Exhaust muffler
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
JP3040121B2
(ja)
|
1988-01-12 |
2000-05-08 |
ジェネンテク,インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
US5720937A
(en)
|
1988-01-12 |
1998-02-24 |
Genentech, Inc. |
In vivo tumor detection assay
|
US20030232010A2
(en)
|
1988-03-29 |
2003-12-18 |
Immunomedics, Inc. |
Improved cytotoxic therapy
|
US5120525A
(en)
|
1988-03-29 |
1992-06-09 |
Immunomedics, Inc. |
Radiolabeled antibody cytotoxic therapy of cancer
|
CA1329119C
(fr)
|
1988-03-29 |
1994-05-03 |
Milton David Goldenberg |
Therapie faisant appel a des agents cytotoxiques
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
ES2181673T3
(es)
|
1991-05-01 |
2003-03-01 |
Jackson H M Found Military Med |
Procedimiento de tratamiento de las enfermedades respiratorias infecciosas.
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
ATE147386T1
(de)
|
1991-08-12 |
1997-01-15 |
Takeda Chemical Industries Ltd |
Kondensierte pyrimidinderivate, ihre herstellung und ihre verwendung als antitumormittel
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
EP0640094A1
(fr)
|
1992-04-24 |
1995-03-01 |
The Board Of Regents, The University Of Texas System |
Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes
|
CA2143642C
(fr)
|
1992-09-15 |
2006-09-05 |
Richard S. Smith |
Peptides immunoreactifs tires du virus epstein-barr
|
US7060283B1
(en)
|
1992-09-15 |
2006-06-13 |
Ortho Diagnostic Systems, Inc. |
Immunoreactive peptides from Epstein-Barr virus
|
US7326535B2
(en)
|
1993-09-15 |
2008-02-05 |
Ortho Diagnostic Systems Inc. |
Immunoreactive peptides from Epstein-Barr virus
|
US5934272A
(en)
|
1993-01-29 |
1999-08-10 |
Aradigm Corporation |
Device and method of creating aerosolized mist of respiratory drug
|
EP0714409A1
(fr)
|
1993-06-16 |
1996-06-05 |
Celltech Therapeutics Limited |
Anticorps
|
WO1995033752A1
(fr)
|
1994-06-09 |
1995-12-14 |
Smithkline Beecham Corporation |
Antagonistes du recepteur de l'endotheline
|
US5686578A
(en)
|
1994-08-05 |
1997-11-11 |
Immunomedics, Inc. |
Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
|
US6132764A
(en)
|
1994-08-05 |
2000-10-17 |
Targesome, Inc. |
Targeted polymerized liposome diagnostic and treatment agents
|
US6019968A
(en)
|
1995-04-14 |
2000-02-01 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
JP2000506165A
(ja)
|
1996-03-04 |
2000-05-23 |
ザ ペン ステイト リサーチ ファウンデーション |
細胞インターナリゼーションを増強するための物質および方法
|
WO1997039774A1
(fr)
|
1996-04-23 |
1997-10-30 |
Novopharm Biotech, Inc. |
Anticorps monoclonal specifique a l'antigene associe au melanome et ses procedes d'utilisation
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
US5855913A
(en)
|
1997-01-16 |
1999-01-05 |
Massachusetts Instite Of Technology |
Particles incorporating surfactants for pulmonary drug delivery
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US6056973A
(en)
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
EP0954282B1
(fr)
|
1997-01-16 |
2005-01-19 |
Massachusetts Institute Of Technology |
Preparation de particules pour inhalation
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
US6303347B1
(en)
|
1997-05-08 |
2001-10-16 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US7541020B2
(en)
|
1997-05-08 |
2009-06-02 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US6113918A
(en)
|
1997-05-08 |
2000-09-05 |
Ribi Immunochem Research, Inc. |
Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
|
US7063967B2
(en)
|
1997-05-08 |
2006-06-20 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US6355257B1
(en)
|
1997-05-08 |
2002-03-12 |
Corixa Corporation |
Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
|
US6764840B2
(en)
|
1997-05-08 |
2004-07-20 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
GB2339430A
(en)
|
1997-05-21 |
2000-01-26 |
Biovation Ltd |
Method for the production of non-immunogenic proteins
|
ATE386802T1
(de)
|
1997-06-12 |
2008-03-15 |
Novartis Int Pharm Ltd |
Künstliche antikörperpolypeptide
|
US6248564B1
(en)
|
1997-08-29 |
2001-06-19 |
Harvard University |
Mutant MHC class I molecules
|
US20040185039A1
(en)
|
2002-08-30 |
2004-09-23 |
Heinz Kohler |
Therapeutic applications of noncovalent dimerizing antibodies
|
US20050033033A1
(en)
|
1998-05-04 |
2005-02-10 |
Heinz Kohler |
Trans-membrane-antibody induced inhibition of apoptosis
|
US20090075339A1
(en)
|
1997-09-19 |
2009-03-19 |
Innexus Biotechnology International Limited |
Autophilic antibodies
|
US20030103984A1
(en)
|
1998-05-04 |
2003-06-05 |
Heinz Kohler |
Fusion proteins of biologically active peptides and antibodies
|
US6238667B1
(en)
|
1997-09-19 |
2001-05-29 |
Heinz Kohler |
Method of affinity cross-linking biologically active immunogenic peptides to antibodies
|
US7569674B2
(en)
|
1998-05-04 |
2009-08-04 |
Innexus Biotechnology International Limited |
Autophilic antibodies
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
ES2340112T3
(es)
|
1998-04-20 |
2010-05-28 |
Glycart Biotechnology Ag |
Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
|
WO1999055715A2
(fr)
|
1998-04-28 |
1999-11-04 |
Galenica Pharmaceuticals, Inc. |
Conjugues d'antigene et de polysaccharide
|
US20090208418A1
(en)
|
2005-04-29 |
2009-08-20 |
Innexus Biotechnology Internaltional Ltd. |
Superantibody synthesis and use in detection, prevention and treatment of disease
|
US7387772B1
(en)
|
1999-06-22 |
2008-06-17 |
Immunimedics, Inc. |
Chimeric, human and humanized anti-CSAP monoclonal antibodies
|
ES2198922T3
(es)
|
1998-06-24 |
2004-02-01 |
Advanced Inhalation Research, Inc. |
Particulas porosas grandes emitadas por un inhalador.
|
WO2000030680A1
(fr)
|
1998-11-23 |
2000-06-02 |
Idec Pharmaceuticals Corporation |
Constructions de proteines chimeres gp39 comprenant un anticorps specifique d'un antigene tumoral
|
WO2000035436A2
(fr)
|
1998-12-16 |
2000-06-22 |
Warner-Lambert Company |
Traitement de l'arthrite a l'aide d'inhibiteurs de la mek
|
WO2000042072A2
(fr)
|
1999-01-15 |
2000-07-20 |
Genentech, Inc. |
Variants polypeptidiques ayant une fonction effectrice alteree
|
US6897044B1
(en)
|
1999-01-28 |
2005-05-24 |
Biogen Idec, Inc. |
Production of tetravalent antibodies
|
EP1176195B1
(fr)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
|
DE60041487D1
(de)
|
1999-05-05 |
2009-03-19 |
Aventis Pharma Ltd |
Substituierte bizyclische verbindungen
|
ATE384744T1
(de)
|
1999-07-29 |
2008-02-15 |
Medarex Inc |
Menschliche antikörper gegen her2/neu
|
SE9903895D0
(sv)
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
US6916925B1
(en)
|
1999-11-05 |
2005-07-12 |
3M Innovative Properties Co. |
Dye labeled imidazoquinoline compounds
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
DE10024069A1
(de)
|
2000-05-17 |
2001-12-13 |
Gluesenkamp Karl Heinz |
Konjugat auf der Basis einer heterobifunktionalen Brückenverbindung, die mit einem Immunmodulator und einer zellerkennenden Einheit substituiert ist
|
AU2001275072A1
(en)
|
2000-05-31 |
2001-12-11 |
The Scripps Research Institute |
Molecular marker for mitosis
|
BRPI0112584B8
(pt)
|
2000-07-19 |
2021-05-25 |
Warner Lambert Co |
ésteres oxigenados de derivados de ácido benzidroxâmico de 4-iodofenilamino, composição farmacêutica e combinação
|
US20060142202A1
(en)
|
2000-12-08 |
2006-06-29 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US20050271663A1
(en)
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
WO2003035835A2
(fr)
|
2001-10-25 |
2003-05-01 |
Genentech, Inc. |
Compositions de glycoproteine
|
TW200303759A
(en)
|
2001-11-27 |
2003-09-16 |
Schering Corp |
Methods for treating cancer
|
CA2467633C
(fr)
|
2001-12-03 |
2012-03-27 |
Abgenix, Inc. |
Categorisation d'anticorps reposant sur des caracteristiques de liaison
|
IL162734A0
(en)
|
2002-02-01 |
2005-11-20 |
Ariad Gene Therapeutics Inc |
Phosphorus-containing compounds & uses thereof
|
ES2555307T3
(es)
|
2002-03-08 |
2015-12-30 |
Eisai R&D Management Co., Ltd. |
Compuestos macrocíclicos útiles como agentes farmacéuticos
|
US20030185835A1
(en)
|
2002-03-19 |
2003-10-02 |
Braun Ralph P. |
Adjuvant for vaccines
|
US20030190308A1
(en)
|
2002-03-19 |
2003-10-09 |
Braun Ralph P. |
Adjuvant
|
DK1487485T3
(da)
|
2002-03-19 |
2011-03-14 |
Powderject Res Ltd |
Imidazoquinolinadjuvanser til DNA-vacciner
|
EP1487486B1
(fr)
|
2002-03-19 |
2009-01-14 |
PowderJect Research Limited |
Imidazoquinolineamines comme adjuvants dans la vaccination d'adn d'hiv
|
CA2480775C
(fr)
|
2002-04-04 |
2016-05-31 |
Coley Pharmaceutical Gmbh |
Oligoribonucleotides immunostimulants contenant de la guanine et de l'uracile
|
US20040248151A1
(en)
|
2002-04-05 |
2004-12-09 |
Ventana Medical Systems, Inc. |
Method for predicting the response to HER2-directed therapy
|
ES2401428T3
(es)
|
2002-04-10 |
2013-04-19 |
Genentech, Inc. |
Variantes de anticuerpos anti-HER2
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
US20090068178A1
(en)
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
KR100485155B1
(ko)
|
2002-05-22 |
2005-04-22 |
주식회사 삼양제넥스 |
효소저항전분을 포함하는 면역활성 증강용 조성물
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
ES2318167T3
(es)
|
2002-07-15 |
2009-05-01 |
The Trustees Of Princeton University |
Compuestos de union a iap.
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
ATE488246T1
(de)
|
2002-08-15 |
2010-12-15 |
3M Innovative Properties Co |
Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
|
WO2004038002A2
(fr)
|
2002-10-25 |
2004-05-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modulation de fonction de cellule dendritique et d'autres reponses cellulaires mediees par des compositions de defensine
|
CA2508660C
(fr)
|
2002-12-23 |
2013-08-20 |
Wyeth |
Anticorps anti pd-1 et utilisations
|
EP2368578A1
(fr)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés
|
CN1767852B
(zh)
|
2003-01-31 |
2010-04-14 |
塞尔德克斯医疗公司 |
抗体疫苗缀合物及其用途
|
US9259459B2
(en)
|
2003-01-31 |
2016-02-16 |
Celldex Therapeutics Inc. |
Antibody vaccine conjugates and uses therefor
|
WO2004071459A2
(fr)
|
2003-02-13 |
2004-08-26 |
3M Innovative Properties Company |
Procedes et compositions associes a des composes modificateurs de reponse immunitaire et recepteur 8 de type toll
|
WO2004078146A2
(fr)
|
2003-03-05 |
2004-09-16 |
Innexus Biotechnology International Limited |
Inhibition d'apoptose induite par un anticorps tansmembranaire
|
CA2521662A1
(fr)
|
2003-04-10 |
2005-01-06 |
3M Innovative Properties Company |
Procedes et compositions permettant de renforcer une reponse immune
|
US20040265351A1
(en)
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
CA2521682A1
(fr)
|
2003-04-10 |
2004-12-16 |
3M Innovative Properties Company |
Distribution de composes modifiant une reponse immunitaire au moyen de materiaux de support particulaires contenant du metal
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
WO2005001855A1
(fr)
|
2003-06-27 |
2005-01-06 |
Tdk Corporation |
Aimant permanent de type r-t-b
|
EP2939693A1
(fr)
|
2003-08-14 |
2015-11-04 |
3M Innovative Properties Company |
Modificateurs de réponse immunitaire modifiée par un lipide
|
WO2005020912A2
(fr)
|
2003-08-25 |
2005-03-10 |
3M Innovative Properties Company |
Administration de composes modificateurs de la reponse immunitaire
|
WO2005018574A2
(fr)
|
2003-08-25 |
2005-03-03 |
3M Innovative Properties Company |
Combinaisons et traitements immunostimulatoires
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
CA2536530A1
(fr)
|
2003-10-01 |
2005-04-14 |
Taro Pharmaceuticals U.S.A., Inc. |
Procede de preparation de 4-amino-1h-imidazo(4,5-c)quinolines et sels d'ajout acides de celles-ci
|
US20050239733A1
(en)
|
2003-10-31 |
2005-10-27 |
Coley Pharmaceutical Gmbh |
Sequence requirements for inhibitory oligonucleotides
|
US20050175630A1
(en)
|
2003-12-23 |
2005-08-11 |
Eyal Raz |
Immunogenic compositions and methods of use thereof
|
US20090028874A1
(en)
|
2003-12-24 |
2009-01-29 |
Leiden University Medical Center |
Synthetic Protein as Tumor-Specific Vaccine
|
JP2007522116A
(ja)
|
2004-01-16 |
2007-08-09 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
コンホメーションが制約されたSmac模倣物およびその使用
|
CA2553871A1
(fr)
|
2004-01-16 |
2005-08-04 |
The Regents Of The University Of Michigan |
Peptidomimetiques de smac et utilisations associees
|
US20060002941A1
(en)
|
2004-01-23 |
2006-01-05 |
Vievax Corp. |
Compositions comprising immune response altering agents and methods of use
|
PT1713806E
(pt)
|
2004-02-14 |
2013-08-27 |
Irm Llc |
Compostos e composições como inibidores da proteína quinase
|
US7345081B2
(en)
|
2004-03-23 |
2008-03-18 |
Genentech, Inc. |
Azabicyclo-octane inhibitors of IAP
|
RU2425838C2
(ru)
|
2004-04-07 |
2011-08-10 |
Новартис Аг |
Ингибиторы iap
|
EP1735010A4
(fr)
|
2004-04-09 |
2008-08-27 |
3M Innovative Properties Co |
Methodes, compositions et preparations pour administration de modificateurs de reponse immunitaire (irm)
|
WO2005107760A1
(fr)
|
2004-04-30 |
2005-11-17 |
Irm Llc |
Composes et compositions en tant qu'inducteurs de la differenciation de keratinocytes
|
GEP20105024B
(en)
|
2004-06-02 |
2010-06-25 |
Takeda Pharmaceuticals Co |
Fused heterocyclic compound
|
EP1753453A2
(fr)
|
2004-06-08 |
2007-02-21 |
Coley Pharmaceutical GmbH |
Oligonucleotide abasique utilise en tant que plate-forme support pour un antigene ainsi qu'un agoniste et un antagoniste immunostimulatoire
|
PL1778718T3
(pl)
|
2004-07-02 |
2015-03-31 |
Genentech Inc |
Inhibitory IAP
|
US7674787B2
(en)
|
2004-07-09 |
2010-03-09 |
The Regents Of The University Of Michigan |
Conformationally constrained Smac mimetics and the uses thereof
|
US20100190688A1
(en)
|
2004-07-12 |
2010-07-29 |
Bin Chao |
Tetrapeptide analogs
|
ES2475207T3
(es)
|
2004-07-15 |
2014-07-10 |
Tetralogic Pharmaceuticals Corporation |
Compuestos de unión a IAP
|
JP2008506683A
(ja)
|
2004-07-18 |
2008-03-06 |
コーリー ファーマシューティカル グループ, リミテッド |
先天免疫応答を誘導するための方法および組成物
|
US7560111B2
(en)
|
2004-07-22 |
2009-07-14 |
Genentech, Inc. |
HER2 antibody composition
|
EP1799256A4
(fr)
|
2004-08-27 |
2009-10-21 |
3M Innovative Properties Co |
Procede pour provoquer une reponse immunitaire contre le hiv
|
NZ580115A
(en)
|
2004-09-23 |
2010-10-29 |
Genentech Inc |
Cysteine engineered antibody light chains and conjugates
|
AU2005289685B2
(en)
|
2004-09-24 |
2009-07-16 |
Amgen Inc. |
Modified Fc molecules
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
CA2586913A1
(fr)
|
2004-11-09 |
2006-05-18 |
University Of Southern California |
Immunite innee ciblee
|
US7632497B2
(en)
|
2004-11-10 |
2009-12-15 |
Macrogenics, Inc. |
Engineering Fc Antibody regions to confer effector function
|
NZ589670A
(en)
|
2004-12-20 |
2013-01-25 |
Genentech Inc |
Pyrrolidine inhibitors of iap
|
RU2383545C2
(ru)
|
2005-03-15 |
2010-03-10 |
Айрм Ллк |
Соединения и композиции в качестве ингибиторов протеинкиназы
|
CA2605749C
(fr)
|
2005-04-26 |
2015-06-30 |
Eisai Co., Ltd. |
Compositions et procedes destines a l'immunotherapie du cancer
|
DK2161336T4
(en)
|
2005-05-09 |
2017-04-24 |
Ono Pharmaceutical Co |
Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
AU2006265108C1
(en)
|
2005-07-01 |
2013-01-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
MX2008002114A
(es)
|
2005-07-21 |
2008-04-17 |
Ardea Biosciences Inc |
Inhibidores de n-(arilamino)-sulfonamida de mek.
|
WO2008020827A2
(fr)
|
2005-08-01 |
2008-02-21 |
Biogen Idec Ma Inc. |
Polypeptides modifiés, immunoconjugués de ceux-ci et procédés apparentés
|
DK1919503T3
(en)
|
2005-08-10 |
2014-12-15 |
Macrogenics Inc |
Identification and preparation of antibodies with variant fc regions and methods of use thereof
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
CN101379195B
(zh)
|
2005-12-20 |
2012-05-09 |
艾德拉药物股份有限公司 |
含有不同长度回文片段的回文免疫调节性寡核苷酸(imotm)的免疫刺激活性
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
US8951528B2
(en)
|
2006-02-22 |
2015-02-10 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
US20080031887A1
(en)
|
2006-06-30 |
2008-02-07 |
Joseph Lustgarten |
Conjugates for inducing targeted immune responses and methods of making and using same
|
US20090074711A1
(en)
|
2006-09-07 |
2009-03-19 |
University Of Southhampton |
Human therapies using chimeric agonistic anti-human cd40 antibody
|
RS53942B1
(en)
|
2006-10-27 |
2015-08-31 |
Genentech Inc. |
Antibodies and Immunoconjugates and Their Use
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
TWI432212B
(zh)
|
2007-04-30 |
2014-04-01 |
Genentech Inc |
Iap抑制劑
|
CA2855098C
(fr)
|
2007-06-18 |
2018-02-27 |
Merck Sharp & Dohme B.V. |
Anticorps diriges contre le recepteur humain de mort programmee pd-1
|
WO2009002939A2
(fr)
|
2007-06-23 |
2008-12-31 |
Innexus Biotechnology International Limited |
Anticorps autophiles
|
RU2523890C2
(ru)
|
2007-09-12 |
2014-07-27 |
Дженентек, Инк. |
Комбинации ингибиторов фосфоинозитид 3-киназы и химиотерапевтических агентов и способы применения
|
WO2009052249A1
(fr)
|
2007-10-19 |
2009-04-23 |
Genentech, Inc. |
Anticorps anti-tenb2 modifiés par des cystéines et conjugués anticorps-médicament
|
JP5348725B2
(ja)
|
2007-10-25 |
2013-11-20 |
ジェネンテック, インコーポレイテッド |
チエノピリミジン化合物の製造方法
|
KR20100097716A
(ko)
|
2007-11-27 |
2010-09-03 |
아블린쓰 엔.브이. |
이종이량체 사이토킨 및/또는 이의 수용체에 대한 아미노산 서열과 이를 포함하는 폴리펩티드
|
US9358307B2
(en)
|
2008-01-25 |
2016-06-07 |
Gavish-Galilee Bio Applications Ltd. |
Targeting of innate immune response to tumor site
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
UY31631A1
(es)
|
2008-02-06 |
2009-09-30 |
|
Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
|
RU2531758C2
(ru)
|
2008-02-11 |
2014-10-27 |
Куретек Лтд. |
Моноклональные антитела для лечения опухолей
|
EP2262837A4
(fr)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
Protéines de liaison avec pd-1
|
DK2247304T3
(en)
|
2008-04-02 |
2016-09-26 |
Macrogenics Inc |
Her2 / neu-specific antibodies and methods of use thereof
|
PT2439212T
(pt)
*
|
2008-05-02 |
2017-03-29 |
Novartis Ag |
Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
KR20110074850A
(ko)
|
2008-08-25 |
2011-07-04 |
앰플리뮨, 인크. |
Pd-1 길항제 및 그의 사용 방법
|
DK2350129T3
(en)
|
2008-08-25 |
2015-08-31 |
Amplimmune Inc |
PREPARATIONS WITH PD-1 ANTAGONISTS AND PROCEDURES FOR USE THEREOF
|
WO2010048149A2
(fr)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
|
SG10201708690SA
(en)
|
2008-12-09 |
2017-12-28 |
Genentech Inc |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
AR074760A1
(es)
|
2008-12-18 |
2011-02-09 |
Metabolex Inc |
Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
|
ES2629337T3
(es)
|
2009-02-09 |
2017-08-08 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
|
JP5918129B2
(ja)
|
2009-06-22 |
2016-05-18 |
メディミューン,エルエルシー |
部位特異的共役のための操作されたFc領域
|
CN102471375A
(zh)
|
2009-07-09 |
2012-05-23 |
F-斯塔生物技术研究和发展有限公司 |
稳定的免疫球蛋白恒定结构域
|
EP2486141B1
(fr)
|
2009-10-07 |
2018-01-10 |
MacroGenics, Inc. |
Polypeptides contenant une région fc qui présentent une fonction d'effecteur améliorée due à des modifications de l'étendue de la fucosylation, et leurs méthodes d'utilisation
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
DK2330131T3
(da)
|
2009-12-07 |
2015-01-05 |
Fundació Privada Inst D Investigació Oncol Gica De Vall Hebron |
Antistoffer mod HER2-trunkeret variant CTF-611
|
ES2594893T3
(es)
|
2009-12-16 |
2016-12-23 |
Abbvie Biotherapeutics Inc. |
Anticuerpos anti HER2 y sus usos
|
CN102167742B
(zh)
|
2010-02-25 |
2014-05-14 |
上海百迈博制药有限公司 |
一种全人源抗her2单克隆抗体、其制备方法及用途
|
US8609095B2
(en)
|
2010-03-04 |
2013-12-17 |
Symphogen A/S |
Anti-HER2 antibodies and compositions
|
US8349585B2
(en)
|
2010-04-15 |
2013-01-08 |
Alper Biotech, Llc |
Monoclonal antibodies against HER2 antigens, and uses therefor
|
WO2011140338A1
(fr)
|
2010-05-05 |
2011-11-10 |
Gatekeeper Pharmaceuticals, Inc. |
Composés modulant l'activité des récepteurs egfr et méthodes pour traiter ou prévenir des troubles à l'aide de ceux-ci
|
JP2013166700A
(ja)
*
|
2010-06-02 |
2013-08-29 |
Dainippon Sumitomo Pharma Co Ltd |
新規4,5−縮環ピリミジン誘導体
|
SG10201600791TA
(en)
|
2010-06-08 |
2016-03-30 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
SI2585470T1
(sl)
|
2010-06-23 |
2017-03-31 |
Hanmi Science Co., Ltd. |
Novi fuzirani derivati pirimidina za inhibicijo aktivnosti tirozin kinaze
|
WO2012021834A1
(fr)
|
2010-08-13 |
2012-02-16 |
Baylor Research Institute |
Nouveaux adjuvants pour vaccins basés sur le ciblage d'adjuvants pour anticorps directement sur les cellules présentant des antigènes
|
US20120321694A1
(en)
|
2010-10-27 |
2012-12-20 |
Daniel Larocque |
Compositions and uses
|
WO2012122396A1
(fr)
|
2011-03-08 |
2012-09-13 |
Baylor Research Institute |
Nouveaux adjuvants pour vaccins basés sur des adjuvants de ciblage direct d'anticorps dirigés contre des cellules présentatrices d'antigènes
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP2570125A1
(fr)
|
2011-09-16 |
2013-03-20 |
Almirall, S.A. |
Ligands du récepteur Ep1
|
EP3539982A3
(fr)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations
|
WO2013179174A1
(fr)
|
2012-05-29 |
2013-12-05 |
Koninklijke Philips N.V. |
Système d'éclairage
|
WO2013184514A1
(fr)
|
2012-06-04 |
2013-12-12 |
Irm Llc |
Méthodes de marquage spécifiques à un site et molécules ainsi produites
|
UA114108C2
(uk)
|
2012-07-10 |
2017-04-25 |
Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем |
Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
|
CN103566377A
(zh)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
CN104837840B
(zh)
*
|
2012-10-10 |
2017-08-08 |
爱尔兰詹森科学公司 |
用于治疗病毒感染及其他疾病的吡咯并[3,2‑d]嘧啶衍生物
|
WO2014083505A1
(fr)
*
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Procédés pour la fabrication de conjugués à partir de protéines contenant du disulfure
|
CN115925957A
(zh)
|
2013-02-08 |
2023-04-07 |
Irm责任有限公司 |
用于修饰抗体以制备免疫缀合物的特定位点
|
WO2014124258A2
(fr)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués
|
US10344060B2
(en)
|
2013-03-12 |
2019-07-09 |
Amgen Inc. |
Potent and selective inhibitors of Nav1.7
|
WO2014151030A1
(fr)
|
2013-03-15 |
2014-09-25 |
Novartis Ag |
Inhibiteurs de la prolifération cellulaire et leurs conjugués
|
CA2903772A1
(fr)
*
|
2013-03-15 |
2014-09-25 |
Novartis Ag |
Conjugues anticorps-medicament
|
RS59500B1
(sr)
|
2013-05-18 |
2019-12-31 |
Aduro Biotech Inc |
Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
|
KR102311234B1
(ko)
|
2013-06-27 |
2021-10-12 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염 및 기타 질환의 치료를 위한 피롤로[3,2-d]피리미딘 유도체
|
MX2016006674A
(es)
|
2013-11-26 |
2016-12-09 |
Novartis Ag |
Metodos para la conjugacion de oxima con polipeptidos modificados con cetona.
|
JP2017503803A
(ja)
|
2014-01-10 |
2017-02-02 |
シャンハイ バーディー バイオテック インコーポレイテッド |
Egfr発現腫瘍を処置するための化合物及び組成物
|
CA2937499A1
(fr)
*
|
2014-01-22 |
2015-07-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Procedes et compositions pour une therapie induite par des anticorps et des cellules dendritiques chargees d'anticorps
|
AU2015229463A1
(en)
|
2014-03-12 |
2016-09-15 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
US10246455B2
(en)
|
2014-04-11 |
2019-04-02 |
Taipei Medical University |
Histone deacetylase inhibitors
|
CN106232603B
(zh)
|
2014-05-01 |
2019-07-05 |
诺华股份有限公司 |
作为toll-样受体7激动剂的化合物和组合物
|
US9944649B2
(en)
*
|
2014-05-01 |
2018-04-17 |
Novartis Ag |
Compounds and compositions as toll-like receptor 7 agonists
|
EA201692530A1
(ru)
|
2014-06-13 |
2017-07-31 |
Новартис Аг |
Цитотоксические пептиды и их конъюгаты
|
WO2016004876A1
(fr)
|
2014-07-09 |
2016-01-14 |
Shanghai Birdie Biotech, Inc. |
Combinaisons anti-pd-l1 pour le traitement des tumeurs
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
CN105440135A
(zh)
|
2014-09-01 |
2016-03-30 |
博笛生物科技有限公司 |
用于***的抗-pd-l1结合物
|
CA2955445A1
(fr)
|
2014-07-17 |
2016-01-21 |
Brian J. Czerniecki |
Fabrication de vaccins a base de cellules dendritiques multi-doses prets a etre injectes, et polytherapie pour bloquer her2 et her3
|
WO2016011347A1
(fr)
|
2014-07-17 |
2016-01-21 |
The Trustees Of The University Of Pennsylvania |
Vaccins à base de cellules dendritiques multi-doses prêts à être injectés, et polythérapie anticancéreuse
|
WO2016020791A1
(fr)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Conjugués anticorps ckit-médicament
|
EP3177321B1
(fr)
|
2014-08-08 |
2020-11-25 |
Oncoquest Pharmaceuticals Inc. |
Anticorps specifique d'antigenes tumoraux et de stimulation de tlr3 pour ameliorer la performance de la therapie par interference du point de contrôle du cancer
|
CN110938076B
(zh)
|
2014-08-15 |
2021-08-10 |
正大天晴药业集团股份有限公司 |
作为tlr7激动剂的吡咯并嘧啶化合物
|
MA41538A
(fr)
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
US9938323B2
(en)
|
2014-11-06 |
2018-04-10 |
Novartis Ag |
Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
|
CN104650228B
(zh)
|
2014-11-26 |
2017-11-28 |
嘉和生物药业有限公司 |
一种全人源her2抗体、其编码基因及应用
|
WO2016091698A1
(fr)
|
2014-12-08 |
2016-06-16 |
F. Hoffmann-La Roche Ag |
Composés 5-amino-6h-thiazolo [4,5-d]pour le traitement et la prophylaxide d'infections virales
|
US9907858B2
(en)
|
2015-01-16 |
2018-03-06 |
Immunwork Inc. |
Peptide core-based multi-arm linkers
|
US10442861B2
(en)
|
2015-05-20 |
2019-10-15 |
Immunwork Inc. |
Molecular constructs with targeting and effector moieties for treating infectious diseases
|
US10975112B2
(en)
|
2015-06-16 |
2021-04-13 |
Hangzhou Dac Biotech Co., Ltd. |
Linkers for conjugation of cell-binding molecules
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
WO2015155753A2
(fr)
|
2015-08-10 |
2015-10-15 |
Suzhou M-Conj Biotech Co., Ltd |
Nouvelles séquences de liaison et leurs utilisation pour la conjugaison spécifique de médicaments à une molécule biologique
|
KR20180037275A
(ko)
|
2015-08-24 |
2018-04-11 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
생물제약 조성물
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
JP6524355B2
(ja)
|
2015-11-05 |
2019-06-05 |
チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Tlr7アゴニストとしての7−(チアゾール−5−イル)ピロロピリミジン化合物
|
EP3411074A4
(fr)
|
2016-02-04 |
2019-09-04 |
Suzhou M-conj Biotech Co., Ltd. |
Lieurs de conjugaison spécifique, immunoconjugués spécifiques de ceux-ci, procédés de fabrication et utilisations desdits conjugués de ceux-ci
|
CN107043379A
(zh)
|
2016-02-05 |
2017-08-15 |
正大天晴药业集团股份有限公司 |
一种tlr7激动剂的晶型a、其制备方法和医药用途
|